Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma
Multiple MyelomaEstablishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After...
LeukemiaLymphoma2 moreRATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant. PURPOSE: This clinical trial is studying how well donor lymphocyte infusion works in treating patients with recurrent or persistent hematologic cancer after donor stem cell transplant.
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
Multiple MyelomaTo evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic...
LeukemiaLymphoma2 moreGiving chemotherapy drugs, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after the transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of giving donor peripheral stem cell transplant together with fludarabine and busulfan and to see how well it works in treating patients with hematologic cancers.
Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem...
Refractory Multiple MyelomaStage I Multiple Myeloma2 moreThis phase II trial studies how well lenalidomide works in treating patients with progressive or recurrent multiple myeloma after a donor stem cell transplant. Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in...
Multiple MyelomaThis is an open-label, multicenter, Phase Ib study to be conducted at approximately eight sites in Europe and the U.S. designed to evaluate the safety, pharmacokinetics, and activity of SGN-40 when combined with bortezomib in patients with multiple myeloma that is relapsed or refractory after at least one prior systemic treatment regimen.
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory...
Multiple MyelomaRenal InsufficiencyThe purpose of this study is to assess the influence of renal impairment on carfilzomib in patients with Multiple Myeloma (MM).
A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy...
Lymphoma (Non-Hodgkin's Lymphoma)Hodgkin's Disease or Multiple Myeloma2 moreThis is a research study intended to further investigate the safety and efficacy of plerixafor in patients with NHL, HD, or MM. Patients who have previously failed stem cell mobilisation attempts or who have previously received more than one autologous or any allogeneic stem cell transplant are not eligible.
Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed...
Multiple MyelomaThis study will evaluate if the combination of Pomalidomide, Cyclophosphamide and Prednisone is safe and provides benefits in patients with multiple myeloma relapsed and/or refractory to lenalidomide.
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood...
Acute Lymphoblastic LeukemiaAcute Myelogenous Leukemia2 moreThe purpose of this study is to find out the effects of using a system called CliniMACS to remove Tcells from blood stem cells. Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD). Some studies have been done with CliniMACS, but the Food and Drug Administration (FDA) has not yet approved it.